CD8A and breast carcinoma: In breast cancer, combined therapy with PD-1 antibodies and guadecitabine (one of the DNMTi) can enhance MHC-I expression and increase CD8 T-cell infiltration in TME, thereby enhancing the therapeutic effect of PD-1 antibodies (Luo et al., 2018).